A cancer vaccine platform at the cutting edge of viral immunotherapy

Dr. García-Sastre is a global leader in research on viral pathogens and vaccines. His laboratory focuses on the molecular biology of influenza viruses and other negative strand RNA viruses. His lab pioneered reverse genetic techniques that enabled a generation of recombinant viruses, and he has made major contributions to the influenza virus field. His research has resulted in more than 480 scientific publications and numerous patents. He brings more than two decades of experience in virology, immunology, and vaccines to the Vaxalto team. A long-standing partnership between Dr. Garcia-Sastre and Dr. Palese led to the development of an influenza vaccine and oncolytic viral immunotherapies. In addition to his roles at Mount Sinai, Dr. García-Sastre is the director of the Center for Research on Influenza Pathogenesis, one of the National Centers of Excellence for Influenza Research and Surveillance. He has also served as the President of the International Society for Vaccines, and he is an elected member of the National Academy of Sciences, among many other honors and accomplishments.
SEE LIST OF PUBLICATIONS

Dr. Skobe is a leading expert in cancer and vascular biology. Research in her laboratory is focused on cancer metastasis, tumor microenvironment, and lymphangiogenesis. She has pioneered the field of tumor lymphangiogenesis, and has made major contributions to research of Vascular Endothelial Growth Factors (VEGFs), including demonstrating the effectiveness of VEGFR-3 inhibition in blocking metastasis. Her discoveries have drawn major attention to the importance of lymphatic vasculature in cancer, a unique area of expertise that she brings to her work at Vaxalto. Dr. Skobe has been elected chair-person of the prestigious Gordon Research Conference on Lymphatic Biology and Pathology, and she received accolades from the Lymphatic Research Foundation for her exceptional contributions to the field, among other distinguished awards.
SEE LIST OF PUBLICATIONS

Dr. Palese is a global leader in the fields of infectious viral diseases and vaccines. Dr. Palese’s research focuses on molecular biology of viruses and host-virus interactions, with particular emphasis on the study of RNA viruses including influenza, paramyxo, and corona (SARS) viruses. Research in the Palese Laboratory has led to the development of influenza vaccines, a Covid-19 vaccine, and an NDV-based oncolytic virus. Dr. Palese brings a robust expertise in viruses and vaccine development to his work at Vaxalto. His long list of professional accolades include the Inventor of the Year Award from the Icahn School of Mount Sinai, the IHV Lifetime Achievement Award for Scientific Contributions from the Institute of Human Virology, and the Drexel Prize in Translational Medicine, among others. Dr. Palese is an elected member of the National Academy of Sciences.
SEE LIST OF PUBLICATIONS

Harry L. Crosby has over three decades of experience in investment banking and private equity. He began his career at Lehman Brothers focused in private equity investing, became managing director at Credit Suisse Financial Sponsors group, and led the financial sponsors group for North America at Merrill Lynch. He is a partner in a leading New York based private equity firm. Mr. Crosby has had broad experience in the health care services industry as both advisor and investor and is the principal investor in Vaxalto Biotherapeutics.

Matthew J. Meyer is chief client corporate development advisor at Wilson Sonsini Goodrich & Rosati, where he leads the firm's life science business advisory practice. Matthew is a seasoned biotech executive and attorney with an extensive track record of success in business roles of increasing responsibility across biopharma, medtech, and precision medicine companies, including Pfizer, Novartis, Myriad and CareDx. At Vaxalto, Matthew leverages this experience to support the buildout, financing, strategy, and growth/scale-up of the company.